CN106138155A - A kind of compositions preventing and treating hepatitis and application thereof - Google Patents
A kind of compositions preventing and treating hepatitis and application thereof Download PDFInfo
- Publication number
- CN106138155A CN106138155A CN201510208255.1A CN201510208255A CN106138155A CN 106138155 A CN106138155 A CN 106138155A CN 201510208255 A CN201510208255 A CN 201510208255A CN 106138155 A CN106138155 A CN 106138155A
- Authority
- CN
- China
- Prior art keywords
- group
- compositions
- hepatitis
- liver
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 208000006454 hepatitis Diseases 0.000 title claims abstract description 22
- 231100000283 hepatitis Toxicity 0.000 title claims abstract description 22
- 239000000284 extract Substances 0.000 claims abstract description 21
- 210000004185 liver Anatomy 0.000 claims abstract description 19
- 235000000421 Lepidium meyenii Nutrition 0.000 claims abstract description 12
- 240000000759 Lepidium meyenii Species 0.000 claims abstract description 12
- 235000012902 lepidium meyenii Nutrition 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- -1 suspensoid Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 230000003908 liver function Effects 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 3
- 241001521901 Tribulus lanuginosus Species 0.000 abstract description 2
- 208000027418 Wounds and injury Diseases 0.000 abstract description 2
- 238000000605 extraction Methods 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract description 2
- 230000001629 suppression Effects 0.000 abstract description 2
- 238000001784 detoxification Methods 0.000 abstract 1
- 230000002443 hepatoprotective effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 23
- 241000700159 Rattus Species 0.000 description 16
- 235000013305 food Nutrition 0.000 description 15
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 13
- 108010082126 Alanine transaminase Proteins 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 8
- 230000006872 improvement Effects 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 208000002353 alcoholic hepatitis Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 229910001751 gemstone Inorganic materials 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a kind of compositions preventing and treating hepatitis and the application in hepatitis thereof.Described compositions contains following active component: Maca extract and tribulus terrestris extraction.Maca extract and Herba Cirsii extract are share by the present invention, it is possible to suppression hepatitis, improve liver detoxification ability, prevent and treat liver function injury, play hepatoprotective, protect the liver, the effect of easing the affected liver.
Description
Technical field
The present invention relates to a kind of compositions preventing and treating hepatitis, belong to biomedicine technical field.
Background technology
Hepatitis is by the active chronic inflammation of liver.Liver is encroached on by virus, antibacterial, parasite, chemical toxicant, medicine and poisonous substance, ethanol etc.,
The cell making liver is destroyed, and the function of liver suffers damage, and it can cause a series of malaise symptoms of health pearl, and liver function index
Exception.
Chinese medicine is wealth most valuable in China's medical science, is the outstanding cultural heritage of the Chinese nation, is also that in world medicine is bright
Jewel.Chinese medicine has had the history of thousands of years in Chinese application, is ancient Chinese working people's culture crystallization of wisdom, from the legendary god of farming the earliest
Tasting BAICAO developing rapidly to modern medicine, Chinese medicine has become the unique theoretical system affecting world's medicine development, owing to Chinese medicine derives from greatly
Natural, pollution-free, evident in efficacy, toxic and side effects is little, has the most become the focus of global concern.
In China's Chinese Traditional Medicine, there are the food materials of a lot " integration of edible and medicinal herbs ", this existing medicine of part medical material and the comprehensive function of food, again can
Meet the demand of nutrition and health care, be have the curing the disease of efficacy of drugs and food palatant, keep fit, the Special food of defying age, directly promoting
Human immune system's function, slow down aging aspect are advantageously.The food materials of " medicine-food two-purpose " are natural food because of its composition, are eaten for a long time, will not
Increase Liver and kidney burden.
Lepidinm meyenii Walp is to originate in the Andean a kind of crucifer of South America.At present in areas such as the Yunnan of China and Xinjiang, there is larger area
Plantation.The aspects such as Maca is improving fertility, improves sexual function, antidepressant, anti-anemia action have the best effect.Herba Cirsii is Compositae Cirsium
Plant, sweet in the mouth, micro-hardship, cool in nature, energy cooling blood for hemostasis, removing toxicity for eliminating carbuncles, clearing heat and relieving fidgetness.
At present, there is not yet Maca extract and tribulus terrestris extraction both active component share, and be used in the relevant report prevented and treated in terms of hepatitis
Road.
Summary of the invention
An object of the present invention is, it is provided that a kind of compositions preventing and treating hepatitis.
Another object of the present invention is to, it is provided that described compositions prevents and treats the application in the medicine of hepatitis, health product, medicine in preparation.
The combination purposes in preventing and treating hepatitis of described integration of edible and medicinal herbs food materials refers in the technical fields such as medicine, food or reagent, be used for preventing,
Protection, treatment hepatitis and the product of directly related disease thereof, be to include one or more in the types such as medicine, reagent, food or health food.
The compositions preventing and treating hepatitis that the present invention provides, containing following raw material: Maca extract and Herba Cirsii extract.
The compositions preventing and treating hepatitis that the present invention provides, above-mentioned Maca extract raw material and Herba Cirsii extract raw material refer to the activity worked in compositions
Composition, said composition can also contain acceptable carrier, i.e. adjuvant.
Wherein, described acceptable carrier can be the conventional selection of this area, it is also possible to be selected from: xylitol, Sorbitol, isomaltulose
In alcohol, isomaltulose, white sugar, ethanol, starch, dextrin, microcrystalline Cellulose, lactose, hydroxypropyl methylcellulose and magnesium stearate one
Plant or multiple.Further, described acceptable carrier is preferred: the one in starch, lactose, magnesium stearate, white sugar and isomaltulose
Or it is multiple.
The present invention confirms through overtesting: Maca extract and Herba Cirsii extract share, it is possible to suppression hepatitis, prevents and treats liver function injury.
The compositions preventing and treating hepatitis that the present invention provides has a good application prospect in preventing and treating hepatitis.
Detailed description of the invention
Present disclosure is illustrated below by embodiment.In the present invention, embodiments discussed below is to preferably illustrate the present invention,
It is not for limiting the scope of the present invention.
Embodiment 1: prevent and treat the preparation of the compositions of hepatitis
Its preparation technology is as follows:
1, Maca extract is by Lepidinm meyenii Walp through water extraction, and withdrawal ratio is 10: 1 (i.e. 10kg Lepidinm meyenii Walp extracts 1kg Maca extract).
2, Herba Cirsii extract is by Herba Cirsii through water extraction, and withdrawal ratio is 15: 1 (i.e. 15kg Lepidinm meyenii Walp extracts 1kg Maca extract).
3, by the extract of step 1 and step 2 with the distribution ratio mixing such as 1: 1.
4: by the scattered paste shape material drying for standby of step 3.
Embodiment 2: the compositions effect to rat non-alcoholic hepatitis
Use high lipid food to feed and set up rat non-alcoholic hepatitis, the detection composition effect to rat non-alcoholic hepatitis.
1, animal
Healthy Wistar rat, male and female half and half, body weight 180～200g, often group 10/cage group support, is divided into 10 groups.Be purchased from Shanghai this
Rec laboratory animal Co., Ltd, the certification of fitness number (the animal quality certification number: SCXK (Shanghai) 2007-0005).Raise in cleaning
Level Animal House.
2, it is administered and is grouped
The high lipid food (cholesterol 2%, sodium cholate 0.5%, propylthiouracil 0.2%, sucrose 5%, Adeps Sus domestica 1O, normal feedstuff 82.3%) of improvement
The medicine suspension with 0.9% normal saline as compositions
Experimental rat is grouped:
Normal group: feed with full nutrition pellet, give and the normal saline of drug study group equivalent.
Model group: the high lipid food of improvement is fed, and gives and the normal saline of drug study group equivalent.
Low dose group: the high lipid food of improvement is fed, and gives the compositions of 0.5g/kg.
Middle dosage group: the high lipid food of improvement is fed, and gives the compositions of 1g/kg.
High dose group: the high lipid food of improvement is fed, and gives the compositions of 2g/kg.
3, experimental technique
Wistar rat is randomly divided into 5 groups: normal group, model group, low dose group, middle dosage group, high dose group.Rat gives the height of improvement
Fat forage feed after gavage gives medicine 4 weeks after 8 weeks, weighs the weight in wet base of rat liver, measure the alanine aminotransferase (ALT) in serum,
AST (AST), T-CHOL (TC) and triglyceride (TG).
4, statistical analysis
Data acquisition is all used by all of dataRepresenting, statistical analysis uses t inspection.
5, experimental result
As shown in table 1, the liver weight of model group is significantly raised, and the liver weight being administered each group is low compared with model group, wherein high dose group and model
Group is compared has significant difference (P ＜ 0.01).
Table 1 rat body weight and liver weight in wet base
*P ＜ 0.05,**P ＜ 0.01, compares with normal group；#P ＜ 0.05,##P ＜ 0.01 compares with model group；
As shown in table 2, the alanine aminotransferase (ALT) that is administered in each group of serum, AST (AST), T-CHOL (TC)
And triglyceride (TG) level substantially reduces, alanine aminotransferase (ALT), Aspartic Acid that compositions can significantly reduce in serum are described
Aminotransferase (AST), T-CHOL (TC) and triglyceride (TG), improve the symptom of hepatitis.
ALT, AST, TC and TG level in each group of serum tested by table 2
*P ＜ 0.05,**P ＜ 0.01, compares with normal group；#P ＜ 0.05,##P ＜ 0.01 compares with model group；
Embodiment 3: the compositions effect to rat alcoholic hepatitis
Ethanol gavage is used to set up rat alcoholic hepatitis, the detection composition effect to rat alcoholic hepatitis.
1, animal
Healthy SD rat, male and female half and half, body weight 180～200g, often group 10/cage group support, is divided into 10 groups.It is purchased from Shanghai Si Laike
Laboratory animal Co., Ltd, the certification of fitness number (the animal quality certification number: SCXK (Shanghai) 2007-0005).Raise and move in cleaning grade
Thing room.
2, it is administered and is grouped
The medicine suspension with 0.9% normal saline as compositions
Experimental rat is grouped:
Normal group: give and the normal saline of drug study group equivalent.
Model group: give and the normal saline of drug study group equivalent.
Low dose group: give the compositions of 0.5g/kg.
Middle dosage group: give the compositions of 1g/kg.
High dose group: give the compositions of 2g/kg.
3, experimental technique
SD rat is randomly divided into 5 groups: normal group, model group, low dose group, middle dosage group, high dose group.Rat gives the basis of improvement
Feedstuff, normal group with distilled water gavage (15ml/kg, 1 day 1 time), model group with 35% ethanol gavage (15ml/kg, 1 day 1 time),
After gavage gives medicine 4 weeks after feeding 8 weeks, weigh the weight in wet base of rat liver, measure the alanine aminotransferase (ALT) in serum, Men Dong
Histidine amino group transferring enzyme (AST).
4, statistical analysis
Data acquisition is all used by all of dataRepresenting, statistical analysis uses t inspection.
5, experimental result
As shown in table 3, the liver weight of model group is significantly raised, and the liver weight being administered each group is low compared with model group, wherein high dose group and middle dose
Amount group has significant difference (P ＜ 0.01) compared with model group.
Table 3 rat body weight and liver weight in wet base
*P ＜ 0.05,**P ＜ 0.01, compares with normal group；#P ＜ 0.05,##P ＜ 0.01 compares with model group；
As shown in table 4, it is administered the alanine aminotransferase in each group of serum (ALT), AST (AST) level substantially reduces,
Alanine aminotransferase (ALT), AST (AST) that compositions can significantly reduce in serum are described, improve the disease of hepatitis
Shape.
ALT and the AST level in each group of serum tested by table 4
*P ＜ 0.05,**P ＜ 0.01, compares with normal group；#P ＜ 0.05,##P ＜ 0.01 compares with model group；
Above-mentioned test result indicate that, the compositions being made up of Maca extract and Herba Cirsii extract can change by reducing liver weight, regulating lipid metabolism
Kind liver function, the lipidosis reducing liver effectively treats hepatitis.
Claims (2)
1. the compositions preventing and treating hepatitis, it is characterised in that containing following raw material: Maca extract and Herba Cirsii extract.
Compositions the most according to claim 1, it is characterised in that said composition galenic pharmacy routinely makes various dosage form, described dosage form bag
Include one or more in tablet, capsule, granule, suspensoid, Emulsion, solution, syrup or injection etc., take oral or injection
One or more route of administration in (including one or more in intravenous injection, intravenous drip, intramuscular injection or subcutaneous injection etc.) etc. carry out liver
Scorching and the prevention of directly related disease, protect or treat.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510208255.1A CN106138155A (en) | 2015-04-27 | 2015-04-27 | A kind of compositions preventing and treating hepatitis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510208255.1A CN106138155A (en) | 2015-04-27 | 2015-04-27 | A kind of compositions preventing and treating hepatitis and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106138155A true CN106138155A (en) | 2016-11-23 |
Family
ID=57347574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510208255.1A Pending CN106138155A (en) | 2015-04-27 | 2015-04-27 | A kind of compositions preventing and treating hepatitis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106138155A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107050088A (en) * | 2017-01-23 | 2017-08-18 | 长春正威生物技术有限公司 | A kind of agate card active ingredient, extracting method and application |
| CN114191461A (en) * | 2021-06-23 | 2022-03-18 | 中国中医科学院中药研究所 | Application of maca in treatment of alcoholic fatty liver |
| CN114601856A (en) * | 2022-03-31 | 2022-06-10 | 中国中医科学院中药研究所 | Application of maca in treatment of non-alcoholic fatty liver disease |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101890073A (en) * | 2010-05-27 | 2010-11-24 | 中南大学 | Chinese medicinal composition for preventing and treating hyperlipaemia and fatty liver and preparation method thereof |
| CN101912137A (en) * | 2007-01-16 | 2010-12-15 | 李明 | Common cephalanoplos herb health-care soft drink |
-
2015
- 2015-04-27 CN CN201510208255.1A patent/CN106138155A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101912137A (en) * | 2007-01-16 | 2010-12-15 | 李明 | Common cephalanoplos herb health-care soft drink |
| CN101890073A (en) * | 2010-05-27 | 2010-11-24 | 中南大学 | Chinese medicinal composition for preventing and treating hyperlipaemia and fatty liver and preparation method thereof |
Non-Patent Citations (5)
| Title |
|---|
| 刘锐 等: ""丹苘软胶囊对非酒精性脂肪肝模型大鼠的药效学研究"", 《中国实验方剂学杂志》 * |
| 王国文 等: ""复方降脂胶囊对高脂血症大鼠模型血脂含量的影响"", 《解放军药学学报》 * |
| 王茵 等: ""SD大鼠血液生化指标正常参考值范围的探讨"", 《卫生毒理学杂志》 * |
| 艾迎春 等: ""中药复方对非酒精性脂肪肝大鼠血清TC、TG、HDL的影响"", 《齐齐哈尔医学院学报》 * |
| 郁志华 等: ""高脂饮食和老化对大鼠心酯及心功能的影响"", 《中国老年学杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107050088A (en) * | 2017-01-23 | 2017-08-18 | 长春正威生物技术有限公司 | A kind of agate card active ingredient, extracting method and application |
| CN114191461A (en) * | 2021-06-23 | 2022-03-18 | 中国中医科学院中药研究所 | Application of maca in treatment of alcoholic fatty liver |
| CN114601856A (en) * | 2022-03-31 | 2022-06-10 | 中国中医科学院中药研究所 | Application of maca in treatment of non-alcoholic fatty liver disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1836687A (en) | Pharmaceutical composition for treating depression and its making method | |
| CN110075216B (en) | Food composition with auxiliary blood fat reducing, weight losing and liver protecting effects and preparation method, preparation and application thereof | |
| CN102058631B (en) | Seabuckthorn leaf extract preparation and preparation method thereof | |
| CN1840166A (en) | Modern Chinese medicinal oral liquid of 'Wen Dan Tang' and preparation method thereof | |
| CN106138155A (en) | A kind of compositions preventing and treating hepatitis and application thereof | |
| CN107551001B (en) | A Chinese medicinal composition for preventing and treating alcoholic hepatic injury and its preparation method | |
| CN104922178B (en) | Hypoglycemic effervescent tablet and application thereof | |
| CN110680902A (en) | Traditional Chinese medicine composition for treating laying hen fatty liver | |
| CN108420890B (en) | Composition with blood fat reducing effect and preparation method thereof | |
| CN103920140B (en) | A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation | |
| CN113288937B (en) | Anti-inflammatory traditional Chinese medicine compound and preparation method and application thereof | |
| CN102091313B (en) | Composition of perilla leaf and ginger, preparation method thereof and application thereof in preparing attenuating synergistic medicament in radiotherapy and chemotherapy of cancer | |
| CN104288164A (en) | Pharmaceutical composition for preventing acute alcoholic liver injury | |
| CN104367673B (en) | A kind of Chinese medicine composition treating Eimeria species | |
| CN103720808B (en) | A kind of composition and use thereof, preparation method with relieving constipation effect | |
| CN102526672A (en) | Traditional Chinese medicine composition, applications and preparation method | |
| CN102526639A (en) | Chinese medicinal composition for treating hyperlipidemia and preparation method thereof | |
| CN102335362B (en) | Traditional Chinese medicine for treating insulin resistance of type 2 diabetes | |
| TWI440465B (en) | Herbal extract mixture for reducing blood lipid and a combination thereof | |
| CN105267968A (en) | Natural medicine composition with weight reducing effect | |
| CN101085048B (en) | Traditional Chinese medicine for detoxicating for animals and preparation method thereof | |
| CN101185668A (en) | Novel preparation for preventing and controlling acquired immuno-deficiency syndrome and protecting liver and detoxication | |
| CN104324302A (en) | Preparation method of anti-coccidiosis traditional Chinese medicine extract | |
| CN106138287A (en) | A kind of integration of edible and medicinal herbs formula preventing and treating hepatitis | |
| TW201806612A (en) | Use of anisomeles indica in manufacture of medicament for anti-fatigue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170209 Address after: 200433 Yangpu District State Road, No. 325, Shanghai Applicant after: Shanghai extractive microbial medicine technology Co., Ltd. Address before: 200433 Yangpu District State Road, Shanghai, No. 325 Applicant before: Zhang Lei |
|
| TA01 | Transfer of patent application right | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161123 |
|
| WD01 | Invention patent application deemed withdrawn after publication |